Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

~ 51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohort ~ Interim results presented at ESMO Virtual Congress 2020 ~ On track to report full top-line results in mid-2021 ~ Potentially favorable safety profile compared to anti-PD-1 therapies ~ Market-disruptive pricing planned in $25 billion PD-(L)1 market

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here